



### Company Overview

CohBar is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar's founders of a novel group of naturally occurring, mitochondrial peptides encoded in the mitochondrial genome, which regulate metabolism, cell death and other important biological functions, and whose activity declines with age. CohBar's efforts focus on the development of these peptides into novel therapeutics that offer the potential to address a broad range of large population and orphan diseases. The company and its founders have discovered more than 100 mitochondrial-derived peptides which may be developed into breakthrough treatments for a number of these diseases with enormous unmet medical needs.

### CohBar Provides Update on CB4211 Phase 1b Study for NASH and Obesity

Mar 30 2020, 8:45 AM EDT

### CohBar Reports Fourth Quarter 2019 Financial Results and Provides Business Update

Mar 12 2020, 4:02 PM EDT

### CohBar to Hold Investor Meetings at the ROTH Virtual Conference

Mar 12 2020, 8:30 AM EDT

### Stock Overview

Symbol	CWBR
Exchange	Nasdaq
Market Cap	54.79m
Last Price	\$1.27
52-Week	\$0.87 - \$3.23

04/08/2020 04:00 PM EDT

### Investor Relations

Jordyn Tarazi  
Director, Investor Relations  
T: (650) 445-4441  
jordyn.tarazi@cohbar.com

### Management Team

#### Steven B. Engle, M.S.

Chief Executive Officer, Director

#### Kenneth C. Cundy, Ph.D.

Chief Scientific Officer

#### Jeffrey F. Biunno, CPA, MBA

Chief Financial Officer, Secretary and Treasurer

#### Jon L. Stern, MBA

Chief Operating Officer, Director

### CohBar, Inc.

1455 Adams Drive  
Suite 2050  
Menlo Park, CA 94025

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.